Blog – Page 8

Molecular profiling can aid in diagnosing cancer or predicting an individual’s risk of developing cancer. After obtaining a specimen from a patient, such as blood or tissue, we can use molecular profiling techniques in a laboratory to evaluate the genes or molecules present in a biological sample.

A recent study published in The Journal of Clinical Oncology: Oncology Practice highlights gaps in molecular profiling among Medicaid patients and presents strategies to reduce inconsistencies in care. The retrospective study focuses on molecular profiling for patients with the estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) subtype of breast cancer. Using data on Medicaid beneficiaries in Ohio, the researchers assessed what factors influenced decisions about which patients underwent molecular profiling.

The researchers obtained data from the Ohio Cancer Incidence Surveillance System and from Medicaid claims data. All patients considered in the analysis had localized or regional-stage ER+/HER2-breast cancer that was diagnosed between 2016 and 2020.

Multiomic analyses identify RORC-expressing DCs enriched in patient-derived malignant ascites and enable functional evaluation.

Night vision often fades first, followed by a narrowing of peripheral vision. In retinitis pigmentosa, this progressive loss can eventually lead to blindness.

An experimental treatment has now helped some patients recover limited visual abilities.

The approach combines a gene injection with special goggles. In a small trial involving 10 people with profound vision loss in both eyes, some participants became better able to detect objects, locate them, and reach toward them while using the device.